Agilon Health Inc (NYSE: AGL) kicked off on Monday, down -5.86% from the previous trading day, before settling in for the closing price of $0.95. Over the past 52 weeks, AGL has traded in a range of $0.71-$6.08.
A company in the Healthcare sector has jumped its sales by 3.29% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -1.74%. With a float of $304.05 million, this company’s outstanding shares have now reached $414.28 million.
Agilon Health Inc (AGL) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Medical Care Facilities Industry. The insider ownership of Agilon Health Inc is 26.63%, while institutional ownership is 69.42%. The most recent insider transaction that took place on Dec 13 ’24, was worth 55,085. In this transaction Director of this company bought 25,000 shares at a rate of $2.20, taking the stock ownership to the 73,166 shares. Before that another transaction happened on Dec 11 ’24, when Company’s Director bought 25,062 for $2.01, making the entire transaction worth $50,269. This insider now owns 66,144 shares in total.
Agilon Health Inc (AGL) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.28 earnings per share (EPS), lower than consensus estimate (set at -0.09) by -0.19. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -1.74% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 27.19% during the next five years compared to 3.29% growth over the previous five years of trading.
Agilon Health Inc (NYSE: AGL) Trading Performance Indicators
Take a look at Agilon Health Inc’s (AGL) current performance indicators. Last quarter, stock had a quick ratio of 1.16. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.06.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.80, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.35 in one year’s time.
